Placeholder Banner

A Patient Advocate’s Perspective on Foreign Price Controls

February 7, 2020
Media Contact
Author-Profile-Andrew-Segerman

In a new video, Cynthia Bens, patient advocate and Senior Vice President of Public Policy at the Personalized Medicine Coalition, shares her views on how adopting foreign price controls for prescription medicines will impact patients in the U.S.

 

“I wouldn’t say the President’s proposal for reference pricing is the right way to deal with drug pricing issues. We need to look at the problem holistically. …
 
“What’s really challenging, right now, is all of the estimates on what the president’s foreign reference pricing proposal really means for patients is that there’s going to be a reduction in research and development. …
 
“The harms of the foreign reference pricing proposal really outweigh the benefits that patients are going to see.” 


To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures.


###
 

Discover More
Ahead of tonight’s State of the Union Address, Jim Greenwood, President and CEO of the Biotechnology Innovation Organization, shared what he hopes President Trump will say to America’s patients counting on the development of new medicines and cures,…
In a new video, Alex Karnal, a life science investor and partner at Deerfield Management, shares why investing in new cures and treatments is personal, and he explains how President Trump’s plan to import foreign price controls would have an …
Rachel King is co-founder and CEO of GlycoMimetics, a biotech company based in Rockville, Maryland that is working hard to develop new treatments for patients with various diseases of the blood. In a new video, Mrs. King explains why President Trump…